Abstract
AbstractThrough the history of rxisk.org, this article explores some of the Web’s effects on the production and circulation of pharmaceutical knowledge. RxISK is an independent website that solicits reports from patients in order to uncover drug-induced harms which clinical trials and national pharmacovigilance schemes fail to identify. The first part of the article locates the origins of the project in the nearly 15-year struggle to obtain recognition and redress for one particular side effect of selective serotonin reuptake inhibitor (SSRI) antidepressants—their ability to trigger violent or suicidal behavior. That struggle, I show, brought to light the ways in which modern evidence-making practices obscure the harms of pharmacological treatment. The second part, based on interviews with the site’s creators, examines how RxISK’s data collection practices seek to convert the Web from a site for the circulation of misinformation into a usable source of new knowledge about drugs. The project’s originality, I argue, lies in its effort to reframe the relation between anecdote and evidence so as to liberate the patient’s voice from the burden of representativeness. Within this reframed epistemology, the project is also freed from the imperative of large-scale data extraction that increasingly dominates the economy of digital health.
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Health (social science)
Reference80 articles.
1. Abramson, J. 2004. Overdosed America: The Broken Promise of American Medicine. New York: HarperCollins.
2. Anderson, C., and A. Herxheimer. 2013. Harnessing Patients’ Awareness of Adverse Reactions to the Drugs They Take. In Understanding and Using Health Experiences: Improving Patient Care, ed. S. Ziebland, 116–126. Oxford: Oxford University Press.
3. Angell, M. 2005. The Truth About Drug Companies: How They Deceive Us and What to Do About It. New York: Random House.
4. Anne-Marie. 2012. Out of My Mind. Driven to Drink, 15 March 2012. https://ssristories.org/out-of-my-mind-driven-to-drink-davidhealy-org/. Accessed 4 Aug 2021.
5. Applbaum, K. 2010. Shadow Science: Zyprexa, Eli Lilly and the Globalization of Pharmaceutical Damage Control. BioSocieties 5 (2): 236–255.